Статья
Фенотип пациентов с легочной гипертензией вследствие патологии левых отделов сердца: особенности патофизиологии и дифференциальной диагностики
Наиболее многочисленной, при этом не до конца изученной остается когорта пациентов с посткапиллярной легочной гипертензией (ЛГ), ассоциированной с заболеваниями левых отделов сердца. В данном обзоре детально представлены патофизиологические аспекты развития ЛГ на фоне патологии левых отделов сердца на примере сердечной недостаточности с низкой/сохранной фракцией выброса, а также описано влияние коморбидной патологии на характер течения ЛГ. Обсуждены особенности дифференциального диагноза посткапиллярной и комбинированной (пост- и прекапиллярной) форм ЛГ, а также подходы к дифференциальному диагнозу данных форм ЛГ с легочной артериальной гипертензией с использованием современных неинвазивных и инвазивных подходов.
1. Galie N., Humbert M., Vachiery J.L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., Ghofrani A., Gomez Sanchez M.A., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L.A., Trindade P.T., Zompatori M., Hoeper M.. 2015 ESC/ ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903-75. doi: 10.1183/13993003.01032-2015.
2. Мартынюк Т.В. Легочная гипертензия при заболеваниях левых отделов сердца. В кн. Легочная гипертензия». Под ред. С.Н. Авдеева. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа; 2019. с. 290-319.
3. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M., Burri H., Butler J., Čelutkienė J., Chioncel O., Cleland J.G.F., Coats A.J.S., Crespo-Leiro M.G., Farmakis D., Gilard M., Heymans S., Hoes A.W., Jaarsma T., Jankowska E.A., Lainscak M., Lam C.S.P., Lyon A.R., McMurray J.J.V., Mebazaa A., Mindham R., Muneretto C., Francesco Piepoli M., Price S., Rosano G.M.C., Ruschitzka F., Kathrine Skibelund A.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
4. Rosenkranz S., Gibbs J.S., Wachter R., De Marco T., VonkNoordegraaf A., Vachiéry J.L. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016;37(12):942-54. doi: 10.1093/eurheartj/ehv512.
5. Евразийские клинические рекомендации по диагностике и лечению легочной гипертензии. Евразийский кардиологический журнал. 2020;1:78-122. doi:10.24411/20764766-2020-10002.
6. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации 2020. Режим доступа: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_LG.pdf (дата обращения 16.02.2021).
7. Hoeper M.M., Ghofrani H.A., Grünig E., Klose H., Olschewski H., Rosenkranz S. Pulmonary Hypertension. Dtsch Arztebl Int. 2017;114(5):73-84. doi: 10.3238/arztebl.2017.0073.
8. Damy T., Goode K.M., Kallvikbacka-Bennett A., Lewinter C., Hobkirk J., Nikitin N.P., Dubois-Randé J.L., Hittinger L., Clark A.L., Cleland J.G. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. Eur Heart J. 2010;31(18):2280-90. doi: 10.1093/eurheartj/ehq245.
9. Bursi F., McNallan S.M., Redfield M.M., Nkomo V.T., Lam C.S., Weston S.A., Jiang R., Roger V.L. Pulmonary pressures Фенотип больных легочной гипертензией группы 2 and death in heart failure: a community study. J Am Coll Cardiol. 2012;59(3):222-31. doi: 10.1016/j.jacc.2011.06.076.
10. Mehra P., Mehta V., Sukhija R., Sinha A.K., Gupta M., Girish M.P., Aronow W.S. Pulmonary hypertension in left heart disease. Arch Med Sci. 2019;15(1):262-273. doi: 10.5114/aoms.2017.68938.
11. Теплова Ю.Е., Ляпина И.Н., Шалева В.А., Кузьмина О.К., Евтушенко А.В., Барбараш О.Л. ”Портрет”пациентов c легочной гипертензией на фоне приобретенного порока митрального клапана сердца до хирургической коррекции. Комплексные проблемы сердечно-сосудистых заболеваний. 2021;10(2S):83-88. doi: 10.17802/2306-1278-2021-102S-83-88.
12. Reddy Y., El-Sabbagh A., Nishimura R. Comparing pulmonary arterial wedge pressure and left ventricular end diastolic pressure for assessment of left-sided filling pressures. JAMA Cardiol 2018; 3:453–454. doi: 10.1001/jamacardio.2018.0318.
13. Alamri A.K., Ma C.L., Ryan J.J. Left heart diseaserelated pulmonary hypertension. Cardiol Clin. 2022;40(1):6976. doi: 10.1016/j.ccl.2021.08.007.
14. Macera F., Vachiéry J.L. Management of pulmonary hypertension in left heart disease. Methodist Debakey Cardiovasc J. 2021;17(2):115-123. doi: 10.14797/RKQN5397.
15. Shah S.J., Borlaug B.A., Kitzman D.W., McCulloch A.D., Blaxall B.C., Agarwal R., Chirinos J.A., Collins S., Deo R.C., Gladwin M.T., Granzier H., Hummel S.L., Kass D.A., Redfield M.M., Sam F., Wang T.J., Desvigne-Nickens P., Adhikari B.B. Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary. Circulation. 2020;141(12):1001-1026. doi: 10.1161/CIRCULATIONAHA.119.041886.
16. Miller W.L., Grill D.E., Borlaug B.A. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail. 2013;1(4):290-299. doi: 10.1016/j.jchf.2013.05.001.
17. Vanderpool R.R., Saul M., Nouraie M., Gladwin M.T., Simon M.A. Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol. 2018;3:298-306. doi: 10.1001/jamacardio.2018.0128.
18. Gerges M., Gerges C., Pistritto A.M., Lang M.B., Trip P., Jakowitsch J., Binder T., Lang I.M. Pulmonary hypertension in heart failure. epidemiology, right ventricular function, and survival. Am J Respir Crit Care Med. 2015;192(10):1234-46. doi: 10.1164/rccm.201503-0529OC.
19. Robbins I.M., Newman J.H., Johnson R.F., Hemnes A.R., Fremont R.D., Piana R.N., Zhao D.X., Byrne D.W. Association of the metabolic syndrome with pulmonary venous hypertension. Chest. 2009;136(1):31-36. doi: 10.1378/chest.08-2008.
20. Thenappan T., Shah S.J., Gomberg-Maitland M., Collander B., Vallakati A., Shroff P., Rich S. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2011;4(3):257-65. doi: 10.1161/CIRCHEARTFAILURE.110.958801.
21. Fayyaz A.U., Edwards W.D., Maleszewski J.J., Konik E.A., DuBrock H.M., Borlaug B.A., Frantz R.P., Jenkins S.M., Redfield M.M. Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation. 2018.;137(17):1796-1810. doi: 10.1161/CIRCULATIONAHA.117.031608.
22. Charalampopoulos A., Lewis R., Hickey P., Durrington C., Elliot C., Condliffe R., Sabroe I., Kiely D.G. Pathophysiology and diagnosis of pulmonary hypertension due to left heart disease. Front Med (Lausanne). 2018;5:174. doi: 10.3389/fmed.2018.00174.
23. Nguyen Q.T., Nsaibia M.J., Sirois M.G., Calderone A., Tardif J.C., Fen Shi Y., Ruiz M., Daneault C., Gagnon L., Grouix B., Laurin P., Dupuis J. PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure. Cardiovasc Res. 2020;116(1):171-182. doi: 10.1093/cvr/cvz034.
24. Guazzi M., Naeije R. Pulmonary hypertension in heart failure: pathophysiology, pathobiology, and emerging clinical perspectives. J Am Coll Cardiol. 2017;69(13):1718-1734. doi: 10.1016/j.jacc.2017.01.051.
25. Bosch L., Lam C.S.P., Gong L., Chan S.P., Sim D., Yeo D., Jaufeerally F., Leong K.T.G., Ong H.Y., Ng T.P., Richards A.M., Arslan F., Ling L.H. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. Eur J Heart Fail. 2017;19(12):1664-1671. doi: 10.1002/ejhf.873.
26. Rommel K.P., von Roeder M., Oberueck C., Latuscynski K., Besler C., Blazek S., Stiermaier T., Fengler K., Adams V., Sandri M., Linke A., Schuler G., Thiele H., Lurz P. Load-independent systolic and diastolic right ventricular function in heart failure with preserved ejection fraction as assessed by resting and handgrip exercise pressure-volume loops. Circ Heart Fail. 2018;11(2):e004121. doi: 10.1161/CIRCHEARTFAILURE.117.004121.
27. Andersen M.J., Hwang S.J., Kane G.C., Melenovsky V., Olson T.P., Fetterly K., Borlaug B.A. Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction. Circ Heart Fail. 2015;8(3):542-50. doi: 10.1161/CIRCHEARTFAILURE.114.002114.
28. Guazzi M., Dixon D., Labate V., Beussink-Nelson L., Bandera F., Cuttica M.J., Shah S.J. RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: stratification of clinical phenotypes and outcomes. JACC Cardiovasc Imaging. 2017;10(10 Pt B):1211-1221. doi: 10.1016/j.jcmg.2016.12.024.
29. van Heerebeek L., Hamdani N., Handoko M.L., Falcao-Pires I., Musters R.J., Kupreishvili K., Ijsselmuiden A.J, Schalkwijk C.G., Bronzwaer J.G., Diamant M., Borbély A., van der Velden J., Stienen G.J., Laarman G.J., Niessen H.W., Paulus W.J. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117(1):43-51. doi: 10.1161/CIRCULATIONAHA.107.728550.
30. Ranchoux B., Nadeau V., Bourgeois A., Provencher S., Tremblay É., Omura J., Coté N., Abu-Alhayja'a R., Dumais V., Nachbar R.T., Tastet L., Dahou A., Breuils-Bonnet S., Marette A., Pibarot P., Dupuis J., Paulin R., Boucherat O., Archer S.L., Bonnet S., Potus F. Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease. Circulation Research. 2019;125(4):449-466. doi: 10.1161/CIRCRESAHA.118.314555.
31. Obokata M., Reddy Y.N.V., Pislaru S.V., Melenovsky V., Borlaug B.A. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017;136:6–19. doi: 10.1161/CIRCULATIONAHA.116.026807.
32. Hieda M., Sarma S., Hearon C.M.Jr., Dias K.A., Martinez J., Samels M., Everding B., Palmer D., Livingston S., Morris M., Howden E., Levine B.D. Increased myocardial stiffness in patients with high-risk left ventricular hypertrophy: the hallmark of stage-b heart failure with preserved ejection fraction. Circulation. 2020;141(2):115-123. doi: 10.1161/CIRCULATIONAHA.119.040332.
33. Paulus W.J., Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263–71. doi: 10.1016/j.jacc.2013.02.092.
34. Reddy Y.N.V., Andersen M.J., Obokata M., Koepp K.E., Kane G.C., Melenovsky V., Olson T.P., Borlaug B.A. Arterial stiffening with exercise in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2017;70(2):136148. doi: 10.1016/j.jacc.2017.05.029.
35. Sabbatini A.R., Kararigas G. Menopause-related estrogendecrease and the pathogenesis of HFpEF: JACC review topic of the week. J Am Coll Cardiol 2020;75:1074–82. doi: 10.1016/j.jacc.2019.12.049.
36. Assad T.R., Hemnes A.R., Larkin E.K., Glazer A.M., Xu M., Wells Q.S., Farber-Eger E.H., Sheng Q., Shyr Y., Harrell F.E., Newman J.H., Brittain E.L. Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension. J Am Coll Cardiol. 2016;68(23):2525-2536. doi: 10.1016/j.jacc.2016.09.942.
37. Caravita S., Faini A., Deboeck G., Bondue A., Naeije R., Parati G., Vachiéry J.L. Pulmonary hypertension and ventilation during exercise: Role of the pre-capillary component. J Heart Lung Transplant. 2017;36(7):754-762. doi: 10.1016/j.healun.2016.12.011.
38. Vachiéry J.L., Tedford R.J., Rosenkranz S., Palazzini M., Lang I., Guazzi M., Coghlan G., Chazova I., De Marco T. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019;53(1):1801897. doi: 10.1183/13993003.01897-2018.
39. Charalampopoulos A., Howard L.S., Tzoulaki I., GinSing W., Grapsa J., Wilkins M.R., Davies R.J., Nihoyannopoulos P., Connolly S.B., Gibbs J.S. Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. Pulm Circ. 2014;4(4):669-78. doi: 10.1086/678512.
40. Guazzi M. Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives. Circ Heart Fail. 2014;7:367-77.
41. Ussavarungsi K., Thomas C.S., Burger C.D. Prevalence of metabolic syndrome in patients with pulmonary hypertension. Clin Respir J. 2017;11(6):721-726. doi: 10.1111/crj.12406.
42. Edmonston D.L., Parikh K.S., Rajagopal S., Shaw L.K., Abraham D., Grabner A., Sparks M.A., Wolf M. Pulmonary hypertension subtypes and mortality in CKD. Am J Kidney Dis. 2020;75(5):713-724. doi: 10.1053/j.ajkd.2019.08.027.
43. Dweik R.A., Rounds S., Erzurum S.C., Archer S., Fagan K., Hassoun P.M., Hill N.S., Humbert M., Kawut S.M., Krowka M., Michelakis E., Morrell N.W., Stenmark K., Tuder И.Н. Ляпина и др. R.M., Newman J.; ATS Committee on Pulmonary Hypertension Phenotypes. An official American Thoracic Society Statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med. 2014;189(3):345-55. doi: 10.1164/rccm.201311-1954ST.
44. Алеевская А.М., Выборов О.Н., Грамович В.В., Мартынюк Т.В. Проблемные аспекты легочной гипертензии вследствие патологии левых отделов сердца: фокус на комбинированную пост/прекапиллярную форму. Терапевтический архив. 2020;92(9):54-62. doi: 10.26442/00403660.2020.09.000450.
45. Naeije R., Vachiery J.L., Yerly P., Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 2013;41(01):217-223. doi: 10.1183/09031936.00074312.
46. Bonderman D., Wexberg P., Martischnig A.M., Heinzl H., Lang M.B., Sadushi R., Skoro-Sajer N., Lang I.M. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J. 2011;37(5):1096-103. doi: 10.1183/09031936.00089610.
47. Jacobs W., Konings T.C., Heymans M.W., Boonstra A., Bogaard H.J., van Rossum A.C., Vonk Noordegraaf A. Noninvasive identification of left-sided heart failure in a population suspected of pulmonary arterial hypertension. Eur Respir J. 2015;46(2):422-30. doi: 10.1183/09031936.00202814.
48. Richter S.E., Roberts K.E., Preston I.R., Hill N.S. A simple derived prediction score for the identification of an elevated pulmonary artery wedge pressure using precatheterization clinical data in patients referred to a Pulmonary Hypertension center. Chest. 2016;149:1261-8. doi: 10.1378/chest.15-0819.
49. Sugimoto T., Bandera F., Generati G., Alfonzetti E., Barletta M., Losito M., Labate V., Rovida M., Caracciolo M., Pappone C., Ciconte G., Guazzi M. Left atrial dynamics during exercise in mitral regurgitation of primary and secondary origin: pathophysiological insights by exercise echocardiography combined with gas exchange analysis. JACC Cardiovasc Imaging. 2020;13(1 Pt 1):25-40. doi: 10.1016/j.jcmg.2018.12.031.